BC Extra | Feb 3, 2017
Financial News

Amgen climbs after CVOT readout

Amgen Inc. (NASDAQ:AMGN) rose $7.95 to $167.53 on Friday, adding about $5.9 billion in market cap, after the company said Repatha evolocumab met the primary endpoint in the Phase III FOURIER cardiovascular outcomes trial. Amgen...
Items per page:
1 - 1 of 1